The Link between NAFLD and Metabolic Syndrome
Diagnostics · 07.02.2023 · 13 (4) · 614
DOI: 10.3390/diagnostics13040614 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 07.02.2023. Verfasst von Fabiana Radu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic syndrome (MetS) is characterized by an association of cardiovascular and diabetes mellitus type 2 risk factors. Although the definition of MetS slightly differs depending on the society that described it, its central diagnostic criteria include impaired fasting glucose, low HDL-cholesterol, elevated triglycerides levels and high blood pressure. Insulin resistance (IR) is believed to be the main cause of MetS and is connected to the level of visceral or intra-abdominal adipose tissue, which could be assessed either by calculating body mass index or by measuring waist circumference. Most recent studies revealed that IR may also be present in non-obese patients, and considered visceral adiposity to be the main effector of MetS’ pathology. Visceral adiposity is strongly linked with hepatic fatty infiltration also known as non-alcoholic fatty liver disease (NAFLD), therefore, the level of fatty acids in the hepatic parenchyma is indirectly linked with MetS, being both a cause and a consequence of this syndrome. Taking into consideration the present pandemic of obesity and its tendency to drift towards a progressively earlier onset due to the Western lifestyle, it leads to an increased NAFLD incidence. Novel therapeutic resources are lifestyle intervention with physical activity, Mediterranean diet, or therapeutic surgical respective metabolic and bariatric surgery or drugs such as SGLT-2i, GLP-1 Ra or vitamin E. NAFLD early diagnosis is important due to its easily available diagnostic tools such as non-invasive tools: clinical and laboratory variables (serum biomarkers): AST to platelet ratio index, fibrosis-4, NAFLD Fibrosis Score, BARD Score, fibro test, enhanced liver fibrosis; imaging-based biomarkers: Controlled attenuation parameter, magnetic resonance imaging proton-density fat fraction, transient elastography (TE) or vibration controlled TE, acoustic radiation force impulse imaging, shear wave elastography, magnetic resonance elastography; and the possibility to prevent its complications, respectively, fibrosis, hepato-cellular carcinoma or liver cirrhosis which can develop into end-stage liver disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- Department of Gastroenterology and Internal Medicine, Clinical Emergency University Hospital, 050098 Bucharest, Romania.
- Department of Gastroenterology, Emergency University Hospital Bucharest, 050098 Bucharest, Romania.
ORCID-Profile: Teodor Salmen
Zitieren
APA
Radu, F., Potcovaru, C. G., Salmen, T., Filip, P. V., Pop, C., & Fierbințeanu-Braticievici, C. (2023). The Link between NAFLD and Metabolic Syndrome. Diagnostics, 13(4), 614. https://doi.org/10.3390/diagnostics13040614
Vancouver
Radu F, Potcovaru CG, Salmen T, Filip PV, Pop C, Fierbințeanu-Braticievici C. The Link between NAFLD and Metabolic Syndrome. Diagnostics. 2023;13(4):614. doi:10.3390/diagnostics13040614
BibTeX
@article{Radu2023,
author = {Radu, Fabiana and Potcovaru, Claudia-Gabriela and Salmen, Teodor and Filip, Petruța Violeta and Pop, Corina and Fierbințeanu-Braticievici, Carmen},
title = {The Link between NAFLD and Metabolic Syndrome},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {4},
pages = {614},
doi = {10.3390/diagnostics13040614}
}
EUVIMED